Coronaviruses Resistant to a 3C-Like Protease Inhibitor Are Attenuated for Replication and Pathogenesis, Revealing a Low Genetic Barrier but High Fitness Cost of Resistance

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Journal of Virology

• Publication date

  2014-08-06

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1128/JVI.01528-14PMID 25100843PMCID PMC4178758
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Repurposing of Clinically Developed Drugs for Treatment of Middle East Respiratory Syndrome Coronavirus Infection

  2014cited by this paper
• ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV.

  2014cited by this paper
• Nidovirus papain-like proteases: Multifunctional enzymes with protease, deubiquitinating and deISGylating activities

  2014cited by this paper
• Repurposing of clinically developed drugs for treatment of Middle East Respiratory Coronavirus 1 Infection

  2014cited by this paper
• First Confirmed Cases of Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Infection in the United States, Updated Information on the Epidemiology of MERS-CoV Infection, and Guidance for the Public, Clinicians, and Public Health Authorities—May 2014

  2014cited by this paper
• A Mouse Model for Betacoronavirus Subgroup 2c Using a Bat Coronavirus Strain HKU5 Variant

  2014cited by this paper
• Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection.

  2014cited by this paper
• Evaluation of SSYA10-001 as a Replication Inhibitor of Severe Acute Respiratory Syndrome, Mouse Hepatitis, and Middle East Respiratory Syndrome Coronaviruses

  2014cited by this paper
• Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection.

  2014cited by this paper
• Screening of an FDA-Approved Compound Library Identifies Four Small-Molecule Inhibitors of Middle East Respiratory Syndrome Coronavirus Replication in Cell Culture

  2014cited by this paper
• Evaluation of SSYA10-001 as a Replication Inhibitor of SARS, MHV and MERS

  2014cited by this paper
• Influenza A(H7N9) virus gains neuraminidase inhibitor resistance without loss of in vivo virulence or transmissibility

  2013cited by this paper
• Discovery of N-(benzo[1,2,3]triazol-1-yl)-N-(benzyl)acetamido)phenyl) carboxamides as severe acute respiratory syndrome coronavirus (SARS-CoV) 3CLpro inhibitors: Identification of ML300 and noncovalent nanomolar inhibitors with an induced-fit binding

  2013cited by this paper
• Discovery, synthesis, and structure-based optimization of a series of N-(tert-butyl)-2-(N-arylamido)-2-(pyridin-3-yl) acetamides (ML188) as potent noncovalent small molecule inhibitors of the severe acute respiratory syndrome coronavirus (SARS-CoV) 3CL protease.

  2013cited by this paper
• Cell-based antiviral screening against coronaviruses: Developing virus-specific and broad-spectrum inhibitors

  2013cited by this paper
• Assessing Activity and Inhibition of Middle East Respiratory Syndrome Coronavirus Papain-Like and 3C-Like Proteases Using Luciferase-Based Biosensors

  2013cited by this paper
• Recent trends in HIV-1 drug resistance.

  2013cited by this paper
• Molecular basis of human immunodeficiency virus type 1 drug resistance: overview and recent developments.

  2013cited by this paper
• Commentary: Middle East Respiratory Syndrome Coronavirus (MERS-CoV): Announcement of the Coronavirus Study Group

  2013cited by this paper
• Foldon unfolding mediates the interconversion between Mpro-C monomer and 3D domain-swapped dimer

  2012cited by this paper
• Design, synthesis and crystallographic analysis of nitrile-based broad-spectrum peptidomimetic inhibitors for coronavirus 3C-like proteases

  2012cited by this paper
• Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia.

  2012cited by this paper
• The Molecular Basis of Drug Resistance against Hepatitis C Virus NS3/4A Protease Inhibitors

  2012cited by this paper
• Hepatitis C virus resistance to protease inhibitors.

  2011cited by this paper
• Recent development of 3C and 3CL protease inhibitors for anti-coronavirus and anti-picornavirus drug discovery.

  2011cited by this paper
• Activation and maturation of SARS-CoV main protease

  2011cited by this paper
• Severe acute respiratory syndrome coronavirus papain-like novel protease inhibitors: design, synthesis, protein-ligand X-ray structure and biological evaluation.

  2010cited by this paper
• Viral resistance to specifically targeted antiviral therapies for hepatitis C (STAT-Cs).

  2010cited by this paper
• Drug resistance against HCV NS3/4A inhibitors is defined by the balance of substrate recognition versus inhibitor binding

  2010cited by this paper
• Resistance of Herpes Simplex Viruses to Nucleoside Analogues: Mechanisms, Prevalence, and Management

  2010cited by this paper
• Rapid Emergence of Protease Inhibitor Resistance in Hepatitis C Virus

  2010cited by this paper
• Characterization of resistance to the protease inhibitor boceprevir in hepatitis C virus–infected patients

  2009cited by this paper
• A Structural View of the Inactivation of the SARS Coronavirus Main Proteinase by Benzotriazole Esters

  2008cited by this paper
• Structure of the Main Protease from a Global Infectious Human Coronavirus, HCoV-HKU1

  2008cited by this paper
• Design, synthesis and antiviral efficacy of a series of potent chloropyridyl ester-derived SARS-CoV 3CLpro inhibitors

  2008cited by this paper
• A noncovalent class of papain-like protease/deubiquitinase inhibitors blocks SARS virus replication

  2008cited by this paper
• Structure-based design, synthesis, and biological evaluation of peptidomimetic SARS-CoV 3CLpro inhibitors

  2007cited by this paper
• Substrate specificity profiling and identification of a new class of inhibitor for the major protease of the SARS coronavirus.

  2007cited by this paper
• Control of coronavirus infection through plasmacytoid dendritic-cell–derived type I interferon

  2007cited by this paper
• Structures of Two Coronavirus Main Proteases: Implications for Substrate Binding and Antiviral Drug Design

  2007cited by this paper
• A Prospective Hospital-Based Study of the Clinical Impact of Non–Severe Acute Respiratory Syndrome (Non-SARS)–Related Human Coronavirus Infection

  2006cited by this paper
• Critical Assessment of Important Regions in the Subunit Association and Catalytic Action of the Severe Acute Respiratory Syndrome Coronavirus Main Protease*

  2005cited by this paper
• Characterization and Complete Genome Sequence of a Novel Coronavirus, Coronavirus HKU1, from Patients with Pneumonia

  2005cited by this paper
• Design and synthesis of peptidomimetic severe acute respiratory syndrome chymotrypsin-like protease inhibitors.

  2005cited by this paper
• Replication and plaque formation of mouse hepatitis virus (MHV-2) in mouse cell line DBT culture

  2005cited by this paper
• Severe acute respiratory syndrome

  2004cited by this paper
• Identification of a new human coronavirus

  2004cited by this paper
• A previously undescribed coronavirus associated with respiratory disease in humans.

  2004cited by this paper
• Quaternary structure of the severe acute respiratory syndrome (SARS) coronavirus main protease.

  2004cited by this paper
• Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study

  2003cited by this paper
• The Severe Acute Respiratory Syndrome

  2003cited by this paper
• The crystal structures of severe acute respiratory syndrome virus main protease and its complex with an inhibitor

  2003cited by this paper
• Coronavirus Main Proteinase (3CLpro) Structure: Basis for Design of Anti-SARS Drugs

  2003cited by this paper
• Systematic Assembly of a Full-Length Infectious cDNA of Mouse Hepatitis Virus Strain A59

  2002cited by this paper
• Structure of coronavirus main proteinase reveals combination of a chymotrypsin fold with an extra α-helical domain

  2002cited by this paper
• RNA Replication of Mouse Hepatitis Virus Takes Place at Double-Membrane Vesicles

  2002cited by this paper
• Virus-encoded proteinases and proteolytic processing in the Nidovirales.

  2000cited by this paper
• Processing of the Coronavirus MHV-JHM Polymerase Polyprotein: Identification of Precursors and Proteolytic Products Spanning 400 Kilodaltons of ORF1a

  1998cited by this paper
• Growth in suckling-mouse brain of "IBV-like" viruses from patients with upper respiratory tract disease.

  1967cited by this paper
• Morphogenesis of Avian Infectious Bronchitis Virus and a Related Human Virus (Strain 229E)

  1967cited by this paper

• Electrophilic warhead engagement and structure-activity relationship of Benzothiazole-based putative covalent inhibitors targeting SARS-CoV-2 Main protease.

  2026cites this paper
• Patient-reported improvements from use of IMC-2 alone and IMC-2 and Paxlovid® in a Long COVID cohort: a case series

  2026cites this paper
• Review of the Crystallized Structures of the SARS-CoV-2 papain-like protease

  2025cites this paper
• Discovery of Inhibitors of SARS-CoV-2 Papain-like Protease Using Molecular Simulation and Markov State Model.

  2025cites this paper
• Evolution of Antiviral Drug Resistance in SARS-CoV-2

  2025cites this paper
• Mutations differentially affecting the coronavirus Mac1 ADP-ribose binding and hydrolysis activities indicate that it promotes multiple stages of the viral replication cycle

  2025cites this paper
• Expression and immunogenicity of non-structural protein 8 of porcine epidemic diarrhea virus

  2024cites this paper
• Investigation of COVID-19 virus mutagenicity and the effect of the NSP13, NSP14, and NSP16 on the -1 ribosomal frameshifting

  2024cites this paper
• Analysis of SARS-CoV-2 Mutations after Nirmatrelvir Treatment in a Lung Cancer Xenograft Mouse Model

  2024cites this paper
• An orally bioavailable SARS-CoV-2 main protease inhibitor exhibits improved affinity and reduced sensitivity to mutations

  2024cites this paper
• Porcine Epidemic Diarrhea: Insights and Progress on Vaccines

  2024cites this paper
• The importance of good practices and false hits for QSAR-driven virtual screening real application: a SARS-CoV-2 main protease (Mpro) case study

  2023cites this paper
• Naturally Occurring Mutations of SARS-CoV-2 Main Protease Confer Drug Resistance to Nirmatrelvir

  2023cites this paper
• Design of SARS-CoV-2 protease inhibitors with improved affinity and reduced sensitivity to mutations

  2023cites this paper
• Halogenated Baicalein as a Promising Antiviral Agent toward SARS-CoV-2 Main Protease

  2022cites this paper
• Recent changes in the mutational dynamics of the SARS-CoV-2 main protease substantiate the danger of emerging resistance to antiviral drugs

  2022cites this paper
• The Efficacious Benefit of 25-Hydroxy Vitamin D to Prevent COVID-19: An In-Silico Study Targeting SARS-CoV-2 Spike Protein

  2022cites this paper
• Molnupiravir Outpatient Treatment for Adults with COVID-19 in a Real-World Setting—A Single Center Experience

  2022cites this paper
• Discovery of the Cryptic Sites of SARS-CoV-2 Papain-like Protease and Analysis of Its Druggability

  2022cites this paper
• NMR Observation of Sulfhydryl Signals in SARS‐CoV‐2 Main Protease Aids Structural Studies

  2022cites this paper
• Evolution of Clinical Care in COVID-Infected Solid Organ Transplant Recipients

  2022cites this paper
• Identifying Small-Molecule Inhibitors of SARS-CoV-2 RNA-Dependent RNA Polymerase by Establishing a Fluorometric Assay

  2022cites this paper
• In silico approach for the development of novel antiviral compounds based on SARS-COV-2 protease inhibition

  2022cites this paper
• Versatile SARS-CoV-2 Reverse-Genetics Systems for the Study of Antiviral Resistance and Replication

  2022cites this paper
• Exploring the therapeutic potential of marine-derived bioactive compounds against COVID-19

  2021cites this paper
• Targeting novel structural and functional features of coronavirus protease nsp5 (3CLpro, Mpro) in the age of COVID-19

  2021cites this paper
• Knowing and combating the enemy: a brief review on SARS-CoV-2 and computational approaches applied to the discovery of drug candidates

  2021influential citation
• A Comparative Analysis of SARS-CoV-2 Antivirals Characterizes 3CLpro Inhibitor PF-00835231 as a Potential New Treatment for COVID-19

  2021cites this paper
• An Overview on the Development of mRNA-Based Vaccines and Their Formulation Strategies for Improved Antigen Expression In Vivo

  2021cites this paper
• Discovery of anti-MERS-CoV small covalent inhibitors through pharmacophore modeling, covalent docking and molecular dynamics simulation

  2021cites this paper
• Current Understanding of Novel Coronavirus: Molecular Pathogenesis, Diagnosis, and Treatment Approaches

  2021cites this paper
• Potential Nutraceuticals for COVID-19

  2021cites this paper
• Structure-guided design of a perampanel-derived pharmacophore targeting the SARS-CoV-2 main protease

  2021cites this paper
• DFT and MD simulation investigation of favipiravir as an emerging antiviral option against viral protease (3CLpro) of SARS-CoV-2

  2021cites this paper
• Mathematical Modeling of Remdesivir to Treat COVID-19: Can Dosing Be Optimized?

  2021cites this paper
• Indole Chloropyridinyl Ester-Derived SARS-CoV-2 3CLpro Inhibitors: Enzyme Inhibition, Antiviral Efficacy, Structure–Activity Relationship, and X-ray Structural Studies

  2021cites this paper
• Covid-19’da Kullanılan İlaçların Hesapsal Çalışmaları

  2021cites this paper
• Chloropyridinyl Esters of Nonsteroidal Anti-Inflammatory Agents and Related Derivatives as Potent SARS-CoV-2 3CL Protease Inhibitors

  2021cites this paper
• Preclinical characterization of an intravenous coronavirus 3CL protease inhibitor for the potential treatment of COVID19

  2021cites this paper
• SARS-CoV-2: Potential Drug Targets and Its Virtual Screening

  2021cites this paper
• The NSP14/NSP10 RNA repair complex as a Pan-coronavirus therapeutic target

  2021cites this paper
• NDS_A_294231 25..51

  2021cites this paper
• Title: Discovery of a Novel Inhibitor of Coronavirus 3CL Protease for the Potential Treatment of COVID-19

  2021cites this paper
• Evolution of resistance to fluoroquinolones by dengue virus serotype 4 provides insight into mechanism of action and consequences for viral fitness

  2020cites this paper
• Drug Development and Medicinal Chemistry Efforts toward SARS‐Coronavirus and Covid‐19 Therapeutics

  2020cites this paper
• The Current and Future State of Vaccines, Antivirals and Gene Therapies Against Emerging Coronaviruses

  2020cites this paper
• Credible Protein Targets and Curative Strategies for COVID-19: a Review

  2020cites this paper
• Porcine epidemic diarrhea virus: Molecular mechanisms of attenuation and vaccines

  2020cites this paper
• In silico exploration of small-molecule α-helix mimetics as inhibitors of SARS-COV-2 attachment to ACE2

  2020cites this paper
• Natural Plant Products: A Less Focused Aspect for the COVID-19 Viral Outbreak

  2020cites this paper
• QSAR Modeling of SARS‐CoV Mpro Inhibitors Identifies Sufugolix, Cenicriviroc, Proglumetacin, and other Drugs as Candidates for Repurposing against SARS‐CoV‐2

  2020cites this paper
• SARS-CoV-2: generalidades bioquímicas y métodos de diagnóstico

  2020cites this paper
• Drawing Comparisons between SARS-CoV-2 and the Animal Coronaviruses

  2020cites this paper
• Repurposing the Combination Drug of Favipiravir, Hydroxychloroquine and Oseltamivir as a Potential Inhibitor Against SARS-CoV-2: A Computational Study

  2020cites this paper
• Lectin Protein as a Promising Component to Functionalize Micelles, Liposomes and Lipid NPs against Coronavirus

  2020cites this paper
• Novel Broad-Spectrum Antiviral Inhibitors Targeting Host Factors Essential for Replication of Pathogenic RNA Viruses

  2020cites this paper
• DNA vaccines against COVID-19: Perspectives and challenges

  2020cites this paper
• Virtual repurposing of ursodeoxycholate and chenodeoxycholate as lead candidates against SARS-Cov2-Envelope protein: A molecular dynamics investigation

  2020cites this paper
• Feline coronavirus drug inhibits the main protease of SARS-CoV-2 and blocks virus replication

  2020cites this paper
• Understanding the Molecular Mechanism(s) of SARS-CoV2 Infection and Propagation in Human to Discover Potential Preventive and Therapeutic Approach

  2020cites this paper
• Recent discovery and development of inhibitors targeting coronaviruses

  2020cites this paper
• Laser irradiated phenothiazines: New potential treatment for COVID-19 explored by molecular docking

  2020cites this paper
• Therapeutic targets and computational approaches on drug development for COVID-19.

  2020cites this paper
• Reverse genetic systems: Rational design of coronavirus live attenuated vaccines with immune sequelae

  2020cites this paper
• Development of a Fluorescence-Based, High-Throughput SARS-CoV-2 3CLpro Reporter Assay

  2020cites this paper
• Development of a simple, interpretable and easily transferable QSAR model for quick screening antiviral databases in search of novel 3C-like protease (3CLpro) enzyme inhibitors against SARS-CoV diseases

  2020cites this paper
• Insights into SARS-CoV-2 genome, structure, evolution, pathogenesis and therapies: Structural genomics approach

  2020cites this paper
• Computational models identify several FDA approved or experimental drugs as putative agents against SARS-CoV-2

  2020cites this paper
• SARS, MERS and SARS-CoV-2 (COVID-19) treatment: a patent review

  2020cites this paper
• Current status of antivirals and druggable targets of SARS CoV-2 and other human pathogenic coronaviruses

  2020cites this paper
• A comparative analysis of SARS-CoV-2 antivirals in human airway models characterizes 3CLpro inhibitor PF-00835231 as a potential new treatment for COVID-19

  2020cites this paper
• Drug repurposing screen identifies masitinib as a 3CLpro inhibitor that blocks replication of SARS-CoV-2 in vitro

  2020cites this paper
• Discovery of a Novel Inhibitor of Coronavirus 3CL Protease as a Clinical Candidate for the Potential Treatment of COVID-19

  2020cites this paper
• Rational design of a new class of protease inhibitors for the potential treatment of coronavirus diseases

  2020cites this paper
• Structure-Guided Mutagenesis Alters Deubiquitinating Activity and Attenuates Pathogenesis of a Murine Coronavirus

  2019cites this paper
• Emerging Highly Virulent Porcine Epidemic Diarrhea Virus: Molecular Mechanisms of Attenuation and Rational Design of Live Attenuated Vaccines

  2019cites this paper
• Coronavirus Interferon Antagonists Differentially Modulate the Host Response during Replication in Macrophages

  2019cites this paper
• Characterization of amino acid substitutions in feline coronavirus 3C-like protease from a cat with feline infectious peritonitis treated with a protease inhibitor

  2019influential citation
• Analysis of Coronavirus Temperature-Sensitive Mutants Reveals an Interplay between the Macrodomain and Papain-Like Protease Impacting Replication and Pathogenesis

  2019cites this paper
• Transmission genetics of drug-resistant hepatitis C virus

  2018cites this paper
• Lead Molecule Prediction and Characterization for Designing MERS-CoV 3C-like Protease Inhibitors: An In silico Approach.

  2018cites this paper
• Molecular interaction study of commercial cyclic peptides and MERS-COV papain-like protease as novel drug candidate for MERS-COV

  2017cites this paper
• Potent and selective inhibition of pathogenic viruses by engineered ubiquitin variants

  2017cites this paper
• Coronavirus nonstructural protein 15 mediates evasion of dsRNA sensors and limits apoptosis in macrophages

  2017cites this paper
• Reversal of the Progression of Fatal Coronavirus Infection in Cats by a Broad-Spectrum Coronavirus Protease Inhibitor

  2016cites this paper
• Understanding the determinants for substrate recognition, regulation of enzymatic activity and the development of broad-spectrum inhibitors of coronavirus 3-chymotrypsin-like proteases

  2015influential citation
• Middle East Respiratory Syndrome-Coronavirus (MERS-CoV): An Updated Overview and Pharmacotherapeutics

  2015cites this paper